Peptide Research Aliases: How to Find the Right Paper Under Another Name

Find peptide studies under alternate names with a sourced alias crosswalk, PubMed query examples and checks for sequence mismatches and evidence limits.

When a peptide search returns little useful research, change the search method before drawing a conclusion about the evidence. Begin with the name you have, identify a traceable alternative name or sequence, and then check the material described in the original paper. Finding a similar word is only the start.

This guide uses Epitalon, Vesugen and Cartalax to demonstrate an original search workflow. It includes a small source-backed crosswalk, example queries and a record template. It does not establish clinical benefit, validate a supplier’s product, or claim to retrieve every relevant study.

Three steps from a label to a paper

Use the following search map as a reading aid. It represents questions to answer, not a guaranteed chain of chemical equivalence.

Our recommendation is to keep all three records. Do not replace the original label with your preferred scientific name and discard the route between them. Another reader should be able to follow how you moved from a catalog, conversation or reference list to the selected paper.

If the bridge is uncertain, mark it as a candidate match. Continue searching without silently promoting the candidate into a confirmed identity. A useful search notebook should preserve exclusions as well as promising results.

A source-backed starting crosswalk

The following entries reflect the specified indexing records or original publications. They are search aids, not independent analytical verification of a physical sample.

Our recommendation: copy the source beside the alias, not into a separate pile of references that obscures which relationship it supports. Avoid treating an unsourced abbreviation as enough to merge two evidence collections. Read the source’s terminology before adding new aliases to the table.

Epitalon: connect the spelling to the sequence

NLM’s supplementary concept record groups Epitalon, Epithalon, Epithalone and Ala-Glu-Asp-Gly as entry terms for alanyl-glutamyl-aspartyl-glycine. The record also lists AE-0 peptide. NLM record.

A 2007 original paper uses Ala-Glu-Asp-Gly in its title and Epithalon in its abstract. Its experiments concerned female rats under different illumination regimes. This gives a direct example of a sequence-to-name connection within a research record. Original abstract.

Our interpretation: searching both a spelling and a sequence can help locate the relevant record, but the connection does not change the experimental setting. Keep “female rats” attached to the study summary. Do not convert a successful search into a claim about human longevity.

Use the Epitalon profile as an entry point for further reading, then return to each original source. If a result uses a related preparation name, inspect its composition before including it. Do not assume that similar naming or a shared research history proves the same administered material.

Vesugen: distinguish this paper from its background references

The 2015 paper on vascular endothelial cell proliferation identifies Vesugen as Lys-Glu-Asp. Its reported experimental work includes cell cultures and molecular docking. The paper’s discussion of earlier clinical work belongs to its background and reference trail; it should not be presented as the design of the experiments reported in this paper. Original published paper.

Our interpretation: after identifying a matching name, ask which section supports the claim you want to describe. An introduction may lead you to another publication, but it should not substitute for reading that publication. Keep the original study and each cited background source in separate rows of your evidence table.

When spelling varies, use the sequence as a cross-check rather than correcting every occurrence automatically. Preserve the spelling in the title when recording the citation. The Vesugen profile provides a starting route into this literature, while the patient-cells article explains why the research setting matters.

Cartalax: a database term still needs checking

NLM’s C572340 record lists Cartalax, T-31 peptide and Ala-Glu-Asp under alanyl-glutamyl-aspartic acid. It also includes the different string H-Asp-Glu-Asp-OH. That string begins with Asp rather than Ala, so it should not be treated as an identical sequence merely because it appears in the same record. NLM indexing record.

The 2015 T-31 paper explicitly identifies T-31 as AED and describes kidney tissue cultures from young and old rats. Its abstract separately identifies T-35 as EDL. Original abstract.

Our interpretation: this is a reason to check the original experiment and retain the discrepancy, not to abandon reference databases. For this reading exercise, use the source-supported T-31/AED connection and do not carry the inconsistent term into the identity match. Also avoid importing results for the separately identified T-35.

The matched paper does not become a human joint trial because a reader encountered the starting name in a joint-related context. Preserve the kidney-culture setting. The Cartalax profile is a companion introduction; the crosswalk here is a method for checking its sources.

Build a query in two passes

PubMed documents OR for alternatives and AND for combining concepts, using uppercase operators and parentheses to group terms. Its Search Details show how a query was translated. Field tags can restrict a term to a particular field and turn off automatic term mapping for that term. PubMed search help.

Our suggested first pass is broad enough to collect name variants. For example, try the following as a starting query, then inspect the translated search and the retrieved records:

(Epitalon OR Epithalon OR Epithalone OR "Ala-Glu-Asp-Gly")

For the second pass, add the research question you are investigating. A starting example would be:

(Epitalon OR Epithalon OR "Ala-Glu-Asp-Gly") AND telomerase

These are illustrative queries, not a validated systematic-review search strategy. Do not report their result counts without running and dating the search. If an exact phrase is not handled as expected, inspect the warning or translated query and revise it deliberately.

Keep a broad first-pass record before adding narrow outcomes or study filters. Our recommendation is to review what each restriction excludes rather than assuming a short results list proves the literature is small.

For the other examples, start with (Vesugen OR "Lys-Glu-Asp") or (Cartalax OR "T-31" OR "Ala-Glu-Asp"), then inspect each candidate’s material description. Keep ambiguous short codes in context. Do not add an unsupported alias merely to increase the number of results.

Record the search so it can be repeated

Use a brief log for every search that supports an article or decision. This is our suggested template rather than an official database requirement.

Our recommendation is to record a stable paper identifier alongside the title, then check both when reopening the source. If a search engine takes you to a third-party summary, use it to locate the original and cite the original for the claim it supports.

Do not present an abstract-only reading as a complete appraisal of methods, supplementary data or bias. State what you actually examined. An accurate access note helps the next reviewer identify what remains to be checked.

Keep discovery separate from evidence appraisal

Once you locate a candidate study, begin a new set of questions: What was administered or measured? Who or what received it? What was the comparator? Which endpoint was assessed? Did the conclusion preserve the result and its uncertainty?

Our recommendation is to avoid counting papers before resolving duplicate reports, related preparations and unmatched materials. A translated title or a later discussion can lead back to the same experiment. Retain a study-level record so additional citations do not automatically become additional independent confirmations.

For a result that appears favorable, read the primary endpoint and comparison before writing a benefit statement. For a sparse search, describe the search limits rather than declaring that no research exists. For a database inconsistency, document it and seek a direct material description instead of selecting the version that best fits the desired conclusion.

Frequently asked questions

Does a matching alias prove a purchased vial matches the paper?

Our assessment: no. The alias connects literature terms. Establishing the identity of a physical sample is a different question that requires appropriate sample-specific evidence. See the COA guide.

Should I use every synonym in a database?

Our recommendation: use synonyms as leads and check any that conflict with the sequence or material description. The Cartalax example shows why the individual term still matters.

Is one unsuccessful name search enough to say there are no studies?

Our assessment: no. Report what you searched and what you found within that scope. Check supported aliases, the sequence and relevant reference trails before making a broader statement.

Sources and review limits

Prepared September 13, 2026. NLM indexing records, official PubMed documentation and selected original papers were checked. Some PubMed pages returned empty direct text, so their indexed original abstracts were used. The Vesugen publication was available as an author-hosted published PDF. This is a focused search tutorial, not an exhaustive evidence review or independent medical review.

• NLM Epitalon concept record.
• Epithalon female-rat study.
• Vesugen original publication.
• NLM Cartalax concept record.
• T-31 kidney-culture study.
• PubMed search documentation.